A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.
There is a critical need to non-invasively and remotely manipulate cells at a distance, particularly for translational applications in animals and humans, researchers said.
The team developed an innovative approach to use mechanogenetics—a field of science that focuses on how physical forces and changes in the mechanical properties of cells and tissues influence gene expression—for the remote control of gene and cell activations. Researchers used ultrasound to mechanically perturb T cells, and then converted the mechanical signals into genetic control of cells.
In this study, researchers show how their remote-controlled mechanogenetics system can be used to engineer chimeric antigen receptor (CAR)-expressing T cells that can target and kill cancer cells. The engineered CAR-T cells have mechano-sensors and genetic transducing modules that can be remotely activated by ultrasound via microbubble amplification.
“CAR-T cell therapy is becoming a paradigm-shifting therapeutic approach for cancer treatment,” said bioengineering professor Peter Yingxiao Wang at the University of California San Diego. “However, major challenges remain before CAR-based immunotherapy can become widely adopted. For instance, the non-specific targeting of CAR-T cells against nonmalignant tissues can be life-threatening. This work could ultimately lead to an unprecedented precision and efficiency in CAR-T cell immunotherapy against solid tumors, while minimizing off-tumor toxicities.”
The team brings together the laboratories of professors Wang and Shu Chien, both bioengineering professors at the Jacobs School of Engineering and the Institute of Engineering in Medicine at UC San Diego, in collaboration with professors Kirk Shung of the University of Southern California and Michel Sadelain at Memorial Sloan Kettering Cancer Center in New York. Researchers present their findings in the Jan. 15 issue of the Proceedings of the National Academy of Sciences, with UC San Diego Ph.D. candidate Yijia Pan as the first author.
Researchers found that microbubbles conjugated to streptavidin can be coupled to the surface of a cell, where mechanosensitive Piezo1 ion channels are expressed. Upon exposure to ultrasound waves, microbubbles vibrate and mechanically stimulate Piezo1 ion channels to let calcium ions inside the cell. This triggers downstream pathways, including calcineurin activation, NFAT dephoshorylation and translocation into the nucleus. The nucleus-translocated NFAT can bind to upstream response elements of genetic transducing modules to initiate gene expression of chimeric antigen receptor (CAR) for the recognition and killing of target cancer cells.
The Latest on: CAR-T cell therapy
- Newmarket boy gets 2nd chance at life with approval of CAR-T cell therapy on September 18, 2018 at 1:46 pm
It was a little over two years ago that the Lathi family was preparing to say goodbye to their son. Cameron Lathi, now 12, was diagnosed with B-cell acute lymphoblastic leukemia (ALL) at the tender ag... […]
- CAR T Cells Could Provide Curative Strategies in Myeloma on September 17, 2018 at 12:19 pm
Encouraging clinical trial findings have demonstrated that chimeric antigen receptor (CAR) T-cell therapy has promise for patients with relapsed/refractory multiple myeloma; however, more data are nee... […]
- Teen First In Indiana To Recieve New Cancer Treatment on September 17, 2018 at 10:06 am
An Indiana teenager is the first in the state to receive a new type of cancer treatment for leukemia. CAR T cell therapy was just approved by the FDA last year. The treatment is a type of immunotherap... […]
- New treatment for children with leukemia has mixed results at UW on September 17, 2018 at 3:38 am
Makena Eighmy, one of two patients featured in a State Journal article in May, is in remission after receiving the $475,000 treatment, known as CAR T-cell therapy, the same month. “She’s been acting l... […]
- CAR-T cell therapy biotech Allogene Therapeutics files for a $100 million IPO on September 14, 2018 at 5:47 am
Allogene Therapeutics, a Phase 1 biotech developing CAR-T cell therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The South San Francisco, CA-based comp... […]
- Role of CAR T-Cell Therapy in Pediatric ALL Continues to Be Refined on September 13, 2018 at 7:53 pm
While clinical trial findings with chimeric antigen receptor (CAR) T-cell therapy have impacted the landscape of pediatric acute lymphoblastic leukemia (ALL), most notably with the 2017 FDA approval o... […]
- Global CAR T Cell Therapy Market is forecasted to be growing at 53% till 2025: Sheer Analytics and Insights on September 11, 2018 at 4:08 am
The global CAR T Cell therapy market in terms of revenue is expected to go rapidly in terms of revenue generation by 2025 at a CAGR of 53% from 2018 to 2025 as per new market research titled Global CA... […]
- Global CAR-T Cell Therapy Market Report 2018 - Market Size, Forecasts, Trials & Trends to 2024 - ResearchAndMarkets.com on September 8, 2018 at 6:53 am
DUBLIN--(BUSINESS WIRE)--The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to ResearchAndMarkets.com's offering. CAR-T cell therapy is a ... […]
- CAR-T Cell Therapy Market, 2018-2024 - Landmark Approvals of CAR-T Cell Therapies by the U.S. FDA and the EMA on September 7, 2018 at 5:15 am
The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to ResearchAndMarkets.com's offering. CAR-T cell therapy has swept the biotech industry by storm ... […]
- Global CAR-T Cell Therapy Market Report 2018 - Market Size, Forecasts, Trials & Trends to 2024 - ResearchAndMarkets.com on September 7, 2018 at 4:56 am
DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to ResearchAndMarkets.com's offering. CAR-T cell therapy is ... […]
via Google News and Bing News